

***** Welcome to STN International *****

NEWS 1 Web Page for STN Seminar Schedule - N. America
NEWS 2 AUG 10 Time limit for inactive STN sessions doubles to 40 minutes
NEWS 3 AUG 18 COMPENDEX indexing changed for the Corporate Source (CS) field
NEWS 4 AUG 24 ENCOMPLIT/ENCOMPLIT2 reloaded and enhanced
NEWS 5 AUG 24 CA/CAPLUS enhanced with legal status information for U.S. patents
NEWS 6 SEP 09 50 Millionth Unique Chemical Substance Recorded in CAS REGISTRY
NEWS 7 SEP 11 WPI DS, WPI INDEX, and WPI X now include Japanese FTERM thesaurus
NEWS 8 OCT 21 Derwent World Patents Index Coverage of Indian and Taiwanese Content Expanded
NEWS 9 OCT 21 Derwent World Patents Index enhanced with human translated claims for Chinese Applications and Utility Models
NEWS 10 OCT 27 Free display of legal status information in CA/CAPLUS, USPATFULL, and USPAT2 in the month of November.

NEWS EXPRESS MAY 26 09 CURRENT WINDOWS VERSION IS V8.4, AND CURRENT DISCOVER FILE IS DATED 06 APRIL 2009.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN customer agreement. This agreement limits use to scientific research. Use for software development or design, implementation of commercial gateways, or use of CAS and STN data in the building of commercial products is prohibited and may result in loss of user privileges and other penalties.

***** STN Columbus *****

FILE 'HOME' ENTERED AT 14:20:09 ON 28 OCT 2009

=> file caplus	
COST IN U.S. DOLLARS	SINCE FILE
TOTAL	ENTRY SESSION
FULL ESTIMATED COST	0.66 0.66

FILE 'CAPLUS' ENTERED AT 14:21:57 ON 28 OCT 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is

held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 28 Oct 2009 VOL 151 ISS 18
FILE LAST UPDATED: 27 Oct 2009 (20091027/ED)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Aug 2009
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Aug 2009

CAPLUS now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2009.

CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy.html>

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s tr1 or (tr(w1))/bi,ab
UNMATCHED RIGHT PARENTHESIS '1))/BI,AB'
The number of right parentheses in a query must be equal to the number of left parentheses.

=> s (tr1 or (tr(w1))/bi,ab	1091 TR1/BI	959
TR1/AB	18826 TR/BI	16344 TR/AB
10376955 1/BI	9444959 1/AB	821
TR(W)1		
L1	1884 (TR1 OR (TR(W)1))/BI,AB	

=> s (cd18 or (cd(w)18) or (cd49b) or (cd(w)49b))/bi,ab		
5386 CD18/BI	4147 CD18/AB	326706
CD/BI	270656 CD/AB	931073 18/BI
852118 18/AB	182 CD(W)18	158 CD49B/BI
142 CD49B/AB	326706 CD/BI	270656
CD/AB	106 49B/BI	90 49B/AB
1 CD(W)49B		
L2	5657 (CD18 OR (CD(W)18) OR (CD49B) OR (CD(W)49B))/BI,AB	

=> s l1 and l2
L3 4 L1 AND L2

=> d his
(FILE 'HOME' ENTERED AT 14:20:09 ON 28 OCT 2009)
FILE 'CAPLUS' ENTERED AT 14:21:57 ON 28 OCT 2009
L1 1884 S (TR1 OR (TR(W)1))/BI,AB
L2 5657 S (CD18 OR (CD(W)18) OR (CD49B) OR (CD(W)49B))/BI,AB
L3 4 S L1 AND L2

=> d l3 1-4 bib ab

L3 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2009:1224075 CAPLUS << LOGINID::20091028>>

TI Increased expression of regulatory ***Tr1*** cells in recurrent hepatitis C after liver transplantation
AU Carpentier, A.; Conti, F.; Stenard, F.; Aoudjehane, L.; Miroux, C.; Podevin, P.; Morales, O.; Chouzenoux, S.; Scatton, O.; Groux, H.; Aurialt, C.; Calmus, Y.; Pancre, V.; Delhem, N.
CS Laboratoire de Biologie Cellulaire, Universite Rene Descartes, Paris, Fr.
SO American Journal of Transplantation (2009), 9(9), 2102-2112 CODEN: AJTMBR; ISSN: 1600-6135
PB Wiley-Blackwell
DT Journal
LA English
AB Immune response failure during HCV infection has been assocd. with the activity of regulatory T cells. Hepatitis C-related cirrhosis is the main reason for liver transplantation. However, 80% of transplanted patients present an accelerated recurrence of the disease. This study assessed the involvement of regulatory T-cell subsets (CD4+ CD25+ cells: 'Treg' and ***CD49b*** + ***CD18*** + cells: 'T regulatory-1' cells), in the recurrence of HCV after liver transplantation, using transcriptomic anal., ELISA assays on serum samples and immunohistochem. on liver biopsies from liver recipients 1 and 5 years after transplantation. Three groups of patients were included: stable HCV-neg. recipients and those with mild and severe hepatitis C recurrence. At 5 years, Treg markers were overexpressed in all HCV+ recipients. By contrast, ***Tr1*** markers were only overexpressed in patients with severe recurrence. At 1 yr, a trend toward the overexpression of ***Tr1*** was noted in patients evolving toward severe recurrence. IL-10 prodn., a characteristic of the ***Tr1*** subset, was enhanced in severe recurrence at both 1 and 5 years. These results suggest that ***Tr1*** are enhanced during severe HCV recurrence after liver transplantation and could be predictive of HCV recurrence. High levels of IL-10 at 1 yr could be predictive of severe recurrence, and high IL-10 producers might warrant more intensive management.

L3 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2006:167774 CAPLUS <<LOGINID::20091028>>
DN 144:231482
TI Regulatory T-cells for use in atherosclerosis therapy
IN Groux, Herve; Tedgui, Alain; Mallat, Ziad; Brun, Valerie
PA Institut National de la Sante et de la Recherche Medicale (INSERM), Fr.; Txcell
SO PCT Int. Appl., 39 pp. CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1 PATENT NO. KIND DATE APPLICATION
NO. DATE -----

PI WO 2006018674 A1 20060223 WO 2004-IB2858
20040811 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GN, GW, GQ, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM CA 2575689 A1 20060223
CA 2004-2575689 20040811 US 20080107663 A1
20080508 US 2007-660113 20070905
PRAI WO 2004-IB2858 W 20040811

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS
DISPLAY FORMAT
AB The authors disclose a method of treating or preventing atherosclerosis comprising (a) an antigen which has been used to activate in vitro a ***Tr1*** cell population and (b) administration of the ***Tr1*** cell population activated. In one example, the authors demonstrate a redn. in atherosclerotic plaque size in ovalbumin-sensitized apoE-knockout mice receiving ovalbumin-specific ***Tr1*** cells.
OSC.G 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)
RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD ALL CITATIONS AVAILABLE IN THE REFORMAT

L3 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2005:451235 CAPLUS <<LOGINID::20091028>>
DN 142:457076
TI Use of lipopeptides for activating T lymphocytes through the skin, and therapeutic use
IN Groux, Herve; Brun, Valerie; Foussat, Arnaud
PA Txcell, Fr.; Institut National de la Sante et de la Recherche Medicale INSERM
SO PCT Int. Appl., 38 pp. CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1 PATENT NO. KIND DATE APPLICATION
NO. DATE -----

PI WO 2005046729 A2 20050526 WO 2004-IB3882
20041105 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG AU 2004288646
A1 20050526 AU 2004-288646 20041105 CA 2545841
A1 20050526 CA 2004-2545841 20041105 EP 1689440
A2 20060816 EP 2004-798985 20041105 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, U, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR, IS US 20070275005 A1 20071129 US 2007-579078
20070616
PRAI FR 2003-13261 A 20031112 WO 2004-IB3882
W 20041105

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS
DISPLAY FORMAT
AB The invention discloses the use of a method for treating or preventing skin diseases and diseases of the mucosa, comprising administering topically to a mammal in need of such a treatment a topical medicinal product comprising a lipopeptide or a mixt. thereof, wherein the lipopeptide comprises a peptide antigen specific for a T cell population, the peptide antigen being coupled covalently with a lipid radical and being capable of activating the T cell population. Such a use is more specifically intended for a transcutaneous application of the topical medicinal product, which is advantageously intended to prevent or treat a skin disease. The invention also relates to pharmaceutical or cosmetic formulations comprising the lipopeptide.

OSC.G 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS
RECORD (1 CITINGS)
RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR
THIS RECORD ALL CITATIONS AVAILABLE IN THE RE
FORMAT

L3 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2005:618 CAPLUS <<LOGINID::20091028>>
DN 142:73419

TI Method for identification of ***TR1*** regulator
lymphocytes by the presence and the expression of specific
molecules, and diagnostic and therapeutic applications

IN Groux, Herve

PA Txcell, Fr.

SO Fr. Demande, 89 pp. CODEN: FRXXBL

DT Patent

LA French

FAN.CNT 1 PATENT NO. KIND DATE APPLICATION

NO. DATE -----

PI FR 2856700 A1 20041231 FR 2003-7601
20030624 FR 2856700 B1 20070608 AU 2004251462
A1 20050106 AU 2004-251462 20040624 CA 2529941
A1 20050106 CA 2004-2529941 20040624 WO
2005000344 A2 20050106 WO 2004-FR1583
20040624 WO 2005000344 A3 20050609 W: AE, AG,
AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA,
NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG,
SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC,
VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA,
SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU,
TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB,
GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF,
BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD,
TG EP 1660118 A2 20060531 EP 2004-767439
20040624 EP 1660118 B1 20080409 R: AT, BE, CH,
DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI,
FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK JP 2007520197 T
20070726 JP 2006-516319 20040624 AT 391513
T 20080415 AT 2004-767439 20040624 ES 2305836
T3 20081101 ES 2004-767439 20040624
PRAI FR 2003-7601 A 20030624 WO 2004-FR1583
W 20040624

AB The invention discloses a method for the identification of
TR1 regulator lymphocytes in a biol. sample based on
the detn. of the simultaneous presence of CD4, ***CD18***
and/or CD11a, ***CD49b*** and, if necessary, by the
description of a overexpression of genes coding for the mols.
CD4, PSGL-1, PECAM-1 and .alpha.V/.beta.3. The invention also
discloses a method for quantification and a method for diagnosis
of autoimmune or inflammatory diseases based on the
aforementioned process of identification. The invention further
discloses a method for enrichment of ***TR1*** regulator
lymphocytes based on the detn. of the simultaneous presence of
these mols. The invention also discloses the use of a compn. so
enriched for the treatment by an autoimmune or inflammatory
disease, in particular Crohn's disease.

OSC.G 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS
RECORD (2 CITINGS)

RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR
THIS RECORD ALL CITATIONS AVAILABLE IN THE RE
FORMAT

=> d his

(FILE 'HOME' ENTERED AT 14:20:09 ON 28 OCT 2009)

FILE 'CAPLUS' ENTERED AT 14:21:57 ON 28 OCT 2009

L1 1884 S (TR1 OR (TR(W1)))/BI,AB

L2 5657 S (CD18 OR (CD(W)18) OR (CD49B) OR
(CD(W)49B))/BI,AB

L3 4 S L1 AND L2

=> log y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY SESSION

FULL ESTIMATED COST

53.82 54.48

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) SINCE

FILE TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

-3.28 -3.28

STN INTERNATIONAL LOGOFF AT 14:23:48 ON 28 OCT 2009